/
GRI
$1.86+$0.04 (+2.20%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.2M
2M shares
52-week range
$1.72 – $80.36
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
20.63%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-371866.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $0 | $0 | $22.5M | $0 |
| Cost of revenue | $612 | $735 | $0 | $73.0K | $50.0K | $57.0K | $4.0K | $4.0K |
| Gross profit | −$612 | −$735 | $0 | −$73.0K | −$50.0K | −$57.0K | −$4.0K | −$4.0K |
| Gross margin | — | — | 0.0% | — | — | — | -0.0% | — |
| R&D | $3.5M | $1.9M | $264.0K | $5.2M | $242.0K | $3.2M | $3.8M | $6.8M |
| Operating income | −$4.3M | −$3.2M | −$1.5M | −$9.3M | −$2.2M | −$11.4M | −$8.2M | −$12.0M |
| EBITDA | −$4.3M | −$3.3M | −$1.5M | −$9.2M | −$2.5M | −$10.9M | −$8.2M | −$12.0M |
| Net income | −$4.3M | −$3.5M | −$2.5M | −$9.3M | −$3.2M | −$13.0M | −$8.2M | −$12.0M |
| Net margin | — | — | -2531.0% | — | — | — | -36.4% | — |
| EPS (diluted) | -822780.00 | -660968.00 | -4693.64 | -2827.16 | -47135.48 | -140450.24 | -1545.88 | -121.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-4.77 | $-5.13–$-4.41 | 2 |
| 2027 | $0 | $-2.54 | $-4.80–$-0.26 | 2 |
| 2028 | $0 | $-0.20 | $-0.20–$-0.20 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$65.25
Price
$1.86
Implied upside
+3408%
Peer comparison
GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
www.gribio.com- Employees
- 5
- IPO / List date
- Apr 24, 2023
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds GRI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GRI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-26 | 1-for-28reverse |
| 2025-02-24 | 1-for-17reverse |
| 2024-06-18 | 1-for-13reverse |
| 2024-01-30 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded GRI yet.
